Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Q1 Sales Up 8.9%, Led by Key Product Growth and Weak Yen
July 28, 2023
- Pfizer Seeks Pediatric ALL Nod for Besponsa in Japan
July 28, 2023
- AbbVie’s Parkinson’s Drug Vyalev Now Available in Japan
July 27, 2023
- Ono Settles I/O Patent Row with AstraZeneca, Wins US$140 Million
July 26, 2023
- Otsuka Ups H1 Earnings Guidance on Bullish Global Products
July 26, 2023
- Astellas, PeptiDream to Pair Up to Discover Novel Protein Degraders
July 26, 2023
- Trodelvy Launch on Horizon, Gilead Japan to Hire Oncology Reps from Early 2024
July 26, 2023
- After CAR-T Transfer, Gilead Sets Cell Therapy as Key Biz Pillar for Growth in Japan
July 26, 2023
- Kyowa Kirin Seeks Autologous Indication for G-Lasta in Japan
July 25, 2023
- Pfizer’s Aplastic Anemia Med Atgam Now Available in Japan
July 25, 2023
- Tarlige Tops GP Promotion in May, Dayvigo Most Pitched for HP: Intage
July 24, 2023
- Daiichi Sankyo Bags FDA Nod for FLT3 Inhibitor in 1st Line AML
July 24, 2023
- 7 Drugs Hit 100 Billion Yen Mark in FY2022 Japan Sales, Largest Number in 17 Years
July 24, 2023
- Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
- Lecanemab Shows Large Effect in Low-Tau Population: Clarity AD
July 21, 2023
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- Japan Approves Roche’s Mpox Diagnostic
July 20, 2023
- Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
- Santen Offloads Entire North American Portfolio to Visiox, Harrow
July 20, 2023
- Kissei Pulls Japan NDA for Spinocerebellar Degeneration Treatment
July 20, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…